Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to evaluate the safety and efficacy of Hyalofast® scaffold with bone marrow aspirate concentrate (BMAC) compared to microfracture in the treatment of symptomatic cartilage defects of the knee.


Clinical Trial Description

- Prospective, randomized, active treatment-controlled, evaluator-blinded (radiologist reviewer and physician evaluator) multicenter study (up to 40 sites in the US and EU). - All subjects that meet preoperative screening eligibility criteria will be randomized to treatment with Hyalofast® with BMAC or Microfracture. - Hyalofast® is a sterile, biodegradable non-woven pad (2 x 2 cm or 5 x 5 cm) that is composed of HYAFF-11®, a benzyl ester of hyaluronic acid. Hyalofast® acts as a biodegradable support for the autologous bone marrow aspirate concentrate. Hyalofast® is soft and conformable and can easily be cut to fit the lesion size. - Autologous bone marrow is harvested from the subject intraoperatively during the Index Procedure. Approximately 60 mL of bone marrow will be aspirated from the subject's iliac crest using the SmartPrep 2 Bone Marrow Processing Pack. The cellular rich portion will be concentrated via the SmartPrep BMAC 2 Centrifuge System at point-of-care to provide 7 mL of bone marrow aspirate concentrate (BMAC). 1 - 2 mLs will be used for post-procedure testing of total nucleated cells, cell viability, and sterility. - Hyalofast® with BMAC is implanted during either a standard knee arthroscopy or min-arthrotomy depending upon surgeon preferences and intra-operative findings. The lesion to be treated will be debrided to a stable cartilage margin. The defect will be sized and Hyalofast® will be cut to fit the lesion area. If necessary, more than one Hyalofast® pad can be overlapped to cover the lesion. 2 mL of BMAC will be loaded per Hyalofast® scaffold and then implanted to cover the defect. Hyalofast® with BMAC readily adheres to the site of application, but, if necessary, can be secured to the defect margins with an FDA-approved fibrin glue. - All subjects will be assessed at intervals post-procedure (1 month, 3 months, 6 months, 12 months, 24 months, and 36 months). - Subjects will be required to follow a strict pre-specified post-surgery rehabilitation protocol specific to the defect location. - Measures to assess effectiveness will be conducted at follow-ups, with the primary effectiveness endpoint assessment done at the 24 month timepoint. - Evaluators doing efficacy assessments of the subject and administering subject-reported outcome instruments will be blinded to the treatment. - Safety will be assessed by the collection of adverse events at all timepoints. - Magnetic Resonance Imaging (MRI) will be conducted at Screening, 1 month, 12 months, 24 months, and 36 months. Evaluation of the MRIs, including the MOCART score, will be done by blinded radiologist reviewers. The one month MRI will be used as the baseline MRI for evaluation of treatment effectiveness. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02659215
Study type Interventional
Source Anika Therapeutics, Inc.
Contact
Status Active, not recruiting
Phase N/A
Start date December 2015
Completion date June 30, 2026

See also
  Status Clinical Trial Phase
Completed NCT01473199 - BioPoly RS Knee Registry Study for Cartilage Defect Replacement N/A
Active, not recruiting NCT01670617 - DeNovo NT Natural Tissue Graft Stratified Knee Study N/A
Active, not recruiting NCT01347892 - DeNovo NT Ankle LDC Study N/A
Completed NCT02203071 - Comparison of BioCartilage Versus Marrow Stimulating Procedure for Cartilage Defects of the Knee
Completed NCT01626677 - Follow-Up Study of CARTISTEM® Versus Microfracture for the Treatment of Knee Articular Cartilage Injury or Defect Phase 3
Active, not recruiting NCT02855073 - Clinical Trial to Compare ReJoinTM to Sodium Hyaluronate Injection for Knee Osteoarthritis Cartilage Defects Phase 2
Terminated NCT01400607 - Neocartilage Implant to Treat Cartilage Lesions of the Knee Phase 3
Completed NCT01290991 - A Study to Evaluate the Safety of Augmentâ„¢ Bone Graft N/A
Terminated NCT00881023 - Cartilage Autograft Implantation System (CAIS) for the Repair of Knee Cartilage Through Cartilage Regeneration N/A
Terminated NCT02542566 - Protected Versus Early Weight Bearing Post Microfracture Surgery N/A
Completed NCT02696876 - Synovium Brushing to Augmented Microfracture for Improved Cartilage Repair N/A
Active, not recruiting NCT02524509 - the Safety and Efficacy Evaluation of Chondron Compared With Mircrofracture of Knee Phase 4
Active, not recruiting NCT02537067 - Efficacy and Safety of Chondron (Autologus Chondrocyte) in Patients With Cartilage Defects in Their Ankle Phase 3
Recruiting NCT02519881 - the Efficacy and Safety of a Modified Microfracture Using Collagen Compared to Those of a Simple Microfracture in Ankle Phase 4
Active, not recruiting NCT02539030 - Comparison of Efficacy and Safety of Microfracture and Modified Microfracture Phase 4
Terminated NCT01410136 - Chondrofix Osteochondral Allograft Prospective Study N/A
Active, not recruiting NCT00885729 - Mesenchymal Stem Cells in a Clinical Trial to Heal Articular Cartilage Defects Phase 1
Terminated NCT01246635 - Smith & Nephew's European Trufit Study N/A